Integra LifeSciences (NASDAQ:IART) Raised to Buy at Argus

Integra LifeSciences (NASDAQ:IART) was upgraded by stock analysts at Argus from a “hold” rating to a “buy” rating in a report released on Thursday, MarketBeat Ratings reports. The brokerage presently has a $25.00 price objective on the life sciences company’s stock. Argus’ price objective indicates a potential upside of 45.35% from the company’s previous close.

Other equities research analysts also recently issued reports about the company. Weiss Ratings raised Integra LifeSciences from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, May 13th. Wall Street Zen upgraded Integra LifeSciences from a “buy” rating to a “strong-buy” rating in a report on Saturday, June 13th. Truist Financial dropped their price target on shares of Integra LifeSciences from $13.00 to $12.00 and set a “hold” rating on the stock in a research note on Wednesday, April 15th. Wells Fargo & Company increased their price objective on shares of Integra LifeSciences from $12.00 to $15.00 and gave the company an “equal weight” rating in a research report on Wednesday, May 6th. Finally, Citigroup upgraded shares of Integra LifeSciences from a “sell” rating to a “neutral” rating and raised their price objective for the company from $11.00 to $16.00 in a research note on Thursday, May 28th. One research analyst has rated the stock with a Buy rating, three have assigned a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, Integra LifeSciences presently has a consensus rating of “Reduce” and an average target price of $16.20.

Integra LifeSciences Price Performance

Shares of NASDAQ IART opened at $17.20 on Thursday. Integra LifeSciences has a fifty-two week low of $8.70 and a fifty-two week high of $18.19. The company has a 50 day simple moving average of $13.76 and a two-hundred day simple moving average of $12.29. The company has a market capitalization of $1.34 billion, a price-to-earnings ratio of -2.66, a P/E/G ratio of 1.23 and a beta of 1.24. The company has a debt-to-equity ratio of 1.75, a quick ratio of 1.95 and a current ratio of 3.38.

Integra LifeSciences (NASDAQ:IART) last issued its quarterly earnings results on Tuesday, May 5th. The life sciences company reported $0.54 EPS for the quarter, topping analysts’ consensus estimates of $0.41 by $0.13. The firm had revenue of $391.92 million for the quarter, compared to analysts’ expectations of $381.81 million. Integra LifeSciences had a positive return on equity of 17.42% and a negative net margin of 30.15%.The business’s revenue for the quarter was up 2.4% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.41 EPS. Integra LifeSciences has set its FY 2026 guidance at 2.400-2.500 EPS and its Q2 2026 guidance at 0.440-0.520 EPS. Analysts expect that Integra LifeSciences will post 2.44 EPS for the current fiscal year.

Institutional Trading of Integra LifeSciences

Large investors have recently added to or reduced their stakes in the business. Osaic Holdings Inc. increased its holdings in Integra LifeSciences by 36.6% during the second quarter. Osaic Holdings Inc. now owns 4,119 shares of the life sciences company’s stock valued at $51,000 after buying an additional 1,104 shares during the last quarter. State of Tennessee Department of Treasury boosted its stake in shares of Integra LifeSciences by 7.9% during the 4th quarter. State of Tennessee Department of Treasury now owns 26,745 shares of the life sciences company’s stock worth $332,000 after acquiring an additional 1,964 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of Integra LifeSciences by 5.1% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 40,441 shares of the life sciences company’s stock valued at $889,000 after acquiring an additional 1,975 shares during the period. Capital Fund Management S.A. increased its stake in shares of Integra LifeSciences by 5.7% in the 3rd quarter. Capital Fund Management S.A. now owns 37,322 shares of the life sciences company’s stock worth $535,000 after purchasing an additional 1,997 shares in the last quarter. Finally, Global Retirement Partners LLC bought a new position in Integra LifeSciences in the 4th quarter worth $25,000. 84.78% of the stock is currently owned by institutional investors.

About Integra LifeSciences

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.